| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1008313011289 |
| P698 | PubMed publication ID | 10355580 |
| P2093 | author name string | C Twelves | |
| S B Kaye | |||
| P J O'Dwyer | |||
| A McDonald | |||
| L Paz-Ares | |||
| L B Grochow | |||
| K Selinger | |||
| J P Stevenson | |||
| J Sludden | |||
| P Wissel | |||
| D DeMaria | |||
| P2860 | cites work | Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro | Q54255888 |
| DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts | Q69360455 | ||
| DNA topoisomerases | Q70095180 | ||
| Determination of GI147211 in human blood by HPLC with fluorescence detection | Q71489054 | ||
| Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer | Q71572036 | ||
| Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I | Q72538750 | ||
| Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas | Q77667993 | ||
| Reporting results of cancer treatment | Q29620070 | ||
| Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen | Q33492322 | ||
| Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration | Q33495553 | ||
| The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor | Q33500497 | ||
| Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy | Q33501194 | ||
| DNA topoisomerase-targeting antitumor drugs can be studied in yeast | Q33654182 | ||
| A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study | Q44583571 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 339-344 | |
| P577 | publication date | 1999-03-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. | |
| P478 | volume | 10 |
| Q48354241 | Biologically active quinoline and quinazoline alkaloids part I. |
| Q37069556 | Cancer therapies utilizing the camptothecins: a review of the in vivo literature |
| Q33194418 | Clinical studies of camptothecin and derivatives |
| Q44711871 | Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells |
| Q37481337 | Novel camptothecin derivatives as topoisomerase I inhibitors |
| Q44512464 | OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. |
| Q34468628 | Perspectives on biologically active camptothecin derivatives |
| Q44813441 | Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia |
| Q61773324 | Recent developments in the clinical activity of topoisomerase-1 inhibitors |
Search more.